文献库搜索 | GeneLibs

Liu(J),Qian(F) Ann Med 2026-12-00

...KRAS/ALK), unraveling how mutation-specific metabolic adaptations contribute to targeted therapy resistance, and explore...

Jia(H),Zhong(Y),Lin(CLS),Mandrinos(S),Woon... J Thorac Dis 2026-03-31

...KRAS, and TROP2, as well as resistance mechanisms, immunotherapy combinations, and the tumor microenvironment. Globally,...

Martínez Rueda(SC),Del Pilar Montilla(M),B... J Clin Res Pediatr Endocrin... 2026-04-16

...KRAS, NRAS, BRAF, CBL, NF1, and SHOC2. The most common phenotypic features were congenital heart defects (80%, 36/45), p...

Mohamed(KS),Elfatairy(K),Crow(J),Holloway(... Int J Surg Pathol 2026-09-00

...KRAS p.G12V activating mutation.DiscussionMLA has a broad differential diagnosis and is often misinterpreted as other ne...

Reyes(J),Del Priore(I),Chaikovsky(AC),Pasn... Cell 2026-05-14

...Kras-mutant cells, we find that oncogenic and tumor-suppressive programs, including those controlled by p53, CDKN2A, and...

Skoufou-Papoutsaki(N),Kemp(R),Adler(S),Mar... Nat Commun 2026-04-16

...KRAS, TP53, FBXW7 and CTNNB1) using targeted sequencing of 76,800 normal colonic glands from 56 patients. We show that c...

Strickland(LN),Liu(W),Demmel(MV),Waller(AM... bioRxiv 2026-04-08

...Kras G12D/+ ; LSL-Trp53 R172H/+ ; Pdx1-Cre (KPC) flank tumor model, we show that serial radiofrequency ablation (RFA) en...

Mizgalska(K),Urbaniak(K),Imbody(DJ),Haura(... bioRxiv 2026-04-14

...KRAS oncogene. Although covalent inhibitors effectively target KRAS G12C, secondary mutations such as G12C/Y96C, G12C/Y9...

Chowdhury(S),Ito(I),Pattalachinti(VK),Yous... bioRxiv 2026-04-10

...KRAS inhibitors. MRTX1133 was highly effective for KRASG12D organoids (IC50=4.1 nM); both KRASG12D and KRASG12V organoid...

Karapidaki(I),Handberg-Thorsager(M),Momose... Development 2026-04-15

...KRas, GAP43 and Src64B) work in all the species we tested.